Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16.


Background: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.

Objective: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.

Methods: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.

Results: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was -70.0% (standard deviation 33.2%) and further decreased to -76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.

Limitations: Because of the lack of a control group and observational design, factors of bias may have been induced.

Conclusion: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.

Keywords: atopic dermatitis; daily practice; disease severity; dupilumab; effectiveness; long-term; safety.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Blepharitis / chemically induced
  • Conjunctivitis / chemically induced
  • Dermatitis, Atopic / drug therapy*
  • Drug Resistance
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Prospective Studies
  • Receptors, Interleukin-4 / antagonists & inhibitors
  • Registries
  • Young Adult


  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Receptors, Interleukin-4
  • dupilumab